The FRS2 (Fibroblast Growth Factor Receptor Substrate 2) antibody is a tool used to study the role of FRS2. a key adaptor protein in fibroblast growth factor (FGF) signaling. FRS2 is a cytoplasmic scaffold protein that binds to activated FGF receptors (FGFRs) upon ligand stimulation, facilitating downstream signal transduction. It contains multiple tyrosine phosphorylation sites that recruit effector proteins like Grb2 and SOS, linking FGFR activation to the MAPK/ERK and PI3K-AKT pathways, which regulate cell proliferation, differentiation, survival, and migration.
FRS2 is crucial in embryonic development, tissue repair, and metabolic homeostasis. Dysregulation of FRS2-mediated signaling is implicated in cancers, developmental disorders, and metabolic diseases. For instance, aberrant FRS2 expression or phosphorylation can drive tumor growth, metastasis, or resistance to therapies in cancers with FGFR pathway mutations. The FRS2 antibody enables detection of FRS2 expression levels, phosphorylation status, and interactions in cellular or tissue samples, aiding research into its biological functions and disease associations. It is widely used in techniques like Western blotting, immunohistochemistry, and co-immunoprecipitation. Development of FRS2-targeted therapies, such as inhibitors disrupting FRS2-FGFR binding, is an emerging area, highlighting its translational relevance. The antibody’s specificity and reliability are critical for validating FRS2 as a biomarker or therapeutic target.